|
|
Volumn 69, Issue 3, 2016, Pages 450-456
|
|
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
a,b
|
|
Author keywords
mTOR; Renal cancer; Survival; TORC2
|
|
Indexed keywords
CHOLESTEROL;
CREATININE;
EVEROLIMUS;
VISTUSERTIB;
ANTINEOPLASTIC AGENT;
MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1;
MORPHOLINE DERIVATIVE;
MULTIPROTEIN COMPLEX;
PROTEIN KINASE INHIBITOR;
TARGET OF RAPAMYCIN KINASE;
TOR COMPLEX 2;
VASCULOTROPIN A;
VEGFA PROTEIN, HUMAN;
ADULT;
AGED;
ANEMIA;
ARTICLE;
CANCER PATIENT;
CHOLESTEROL BLOOD LEVEL;
CLINICAL ARTICLE;
CONSTIPATION;
CONTROLLED STUDY;
COUGHING;
CREATININE BLOOD LEVEL;
DECREASED APPETITE;
DIARRHEA;
DRUG EFFICACY;
DYSPNEA;
FATIGUE;
FEMALE;
HUMAN;
HYPERCALCEMIA;
HYPERGLYCEMIA;
HYPERTRIGLYCERIDEMIA;
HYPOCALCEMIA;
INFECTION;
KIDNEY METASTASIS;
LETHARGY;
LIVER FUNCTION TEST;
MALE;
MULTICENTER STUDY;
NAUSEA;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
TREATMENT RESPONSE;
UNITED KINGDOM;
VOMITING;
ANTAGONISTS AND INHIBITORS;
CARCINOMA, RENAL CELL;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
EARLY TERMINATION OF CLINICAL TRIAL;
KAPLAN MEIER METHOD;
KIDNEY NEOPLASMS;
METABOLISM;
MIDDLE AGED;
MOLECULARLY TARGETED THERAPY;
MORTALITY;
PATHOLOGY;
SECONDARY;
TIME FACTOR;
TREATMENT OUTCOME;
AGED;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
EARLY TERMINATION OF CLINICAL TRIALS;
EVEROLIMUS;
FEMALE;
HUMANS;
KAPLAN-MEIER ESTIMATE;
KIDNEY NEOPLASMS;
MALE;
MIDDLE AGED;
MOLECULAR TARGETED THERAPY;
MORPHOLINES;
MULTIPROTEIN COMPLEXES;
PROTEIN KINASE INHIBITORS;
TIME FACTORS;
TOR SERINE-THREONINE KINASES;
TREATMENT OUTCOME;
UNITED KINGDOM;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 84941236891
PISSN: 03022838
EISSN: 18737560
Source Type: Journal
DOI: 10.1016/j.eururo.2015.08.035 Document Type: Article |
|
Times cited : (85)
|
|
References (10)
|
